Myriad myPlan™ Lung Cancer measures
expression levels of critical cell cycle genes. Combined with pathologic
tumor stage, the result is correlated with the 5-year risk of lung cancer
death—guiding physicians in making
chemotherapy decisions for early-stage patients.
Myriad myPath™ Melanoma is a unique molecular test created specifically for difficult-to-diagnose melanoma cases. By analyzing 23 genes, the test provides valuable additive molecular information unavailable from any other method for a more informed diagnosis.
Prolaris® measures the expression level of genes involved with tumor proliferation, providing physicians with unique additional information about a patient’s prostate cancer prognosis and may be used with other clinical factors - providing valuable insight into treatment planning.
Myriad ResultsNow™ electronically delivers Myriad test results. Easily view your patient’s test results from anywhere there is an internet connection. View from your office, home, on any hand-held device.
In some states* existing laws require healthcare providers (HCPs) to obtain informed consent for genetic tests. Due to changing state laws and regulations, it is the HCP’s responsibility to verify whether they practice in a state where informed consent is required prior to ordering genetic testing. If the HCP does practice in a state where informed consent is required, there is a section on the Test Request Form (TRF) labeled Healthcare Provider’s Signature where a signature is required to begin test processing. A copy of an Informed Consent Form is available below (also included in the test kit). Please contact your Myriad Customer Service Specialist at 800-469-7423 for additional information.
Informed Consent for Prolaris® - Describes the benefits and limitations of Prolaris testing to determine risk for prostate cancer disease progression.
Informed Consent For TheraGuide® - Describes the benefits, risks, and limitations of genetic testing to determine risk for developing toxicity to the family of drugs related to 5-fluorouracil (5-FU).
*These states include, but are not limited to, Alaska, New Mexico, Massachusetts, South Carolina, New York, Arizona and Florida.
BRACAnalysis, COLARIS, COLARIS AP, MELARIS, Myriad myPath, myPlan, myRisk, TheraGuide, PREZEON, PANEXIA, and
Prolaris are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions